JNJ-39393406

DRUG4 trials

Sponsors

Janssen Pharmaceutica N.V., Belgium, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tangent Data

Conditions

Alzheimer's DiseaseCognition DisordersDepressionHealthyHealthy VolunteersSchizophrenia

Phase 1

The Effect of JNJ-39393406 on Event Related Potentials in Stable Schizophrenic Patients

TerminatedNCT01137799

Janssen Pharmaceutica N.V., BelgiumAlzheimer's Disease, Cognition Disorders, Schizophrenia

Start: 2009-08-31End: 2011-03-31Updated: 2012-11-08

A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers

CompletedNCT01556217

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy Volunteers

Start: 2010-09-30End: 2010-11-30Updated: 2013-07-24

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39393406 in Healthy Participants

CompletedNCT02023255

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy

Start: 2009-01-31End: 2009-06-30Updated: 2014-01-24

Phase 2

The Effects of JNJ-39393406 on Psychometric Performance and Residual Depressive

CompletedNCT02677207

Tangent DataDepression

Start: 2016-02-29End: 2017-07-31Updated: 2020-05-22

Related Papers

Impact of frequent cerebrospinal fluid sampling on Aβ levels: systematic approach to elucidate influencing factors

Alzheimer s Research & Therapy2016-05-1911 citations